TY - JOUR T1 - Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis JF - medRxiv DO - 10.1101/2020.04.23.20077123 SP - 2020.04.23.20077123 AU - Danielle Klinger AU - Ido Blass AU - Nadav Rappoport AU - Michal Linial Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/29/2020.04.23.20077123.abstract N2 - COVID-19 started in Hubei province in China and has spread to 210 countries within 3 months. The statistic of COVID-19 across the world is reported daily, providing a dynamic perspective for each country. We tested the hypothesis that the vaccination against tuberculosis with BCG correlates with better outcomes for COVID-19 patients. To this end, we combined the information on demography, economy, major chronic diseases, and immunization policies with the COVID-19 outcomes. We filtered out at a fixed date all countries that were below a predetermined value for population size and number of COVID-19 deaths per million (DPM). Altogether, 55 countries, covering 62.9% of the world population, met our criteria and were analyzed. To allow a reliable comparison between countries, each was aligned to a critical alignment threshold date (0.5 DPM). We found that the years of BCG admission are negatively correlated with DPM at varying times post alignment. Results from multivariable regression tests with 22 quantitative properties of each country and its population substantiate the dominant contribution of BCG admission years to the COVID-19 outcomes. Analyzing countries according to an age group partition across several time-points, reveals that the strongest correlation is attributed to the coverage in BCG vaccination of the young population (<25 years), to a lesser degree the middle age group (25-64 years), while BCG coverage status of the elderly (>65 years) was insignificant. More specifically, the signal is attributed to recent immunizations (last 15 years) rather than past policies. We propose that BCG immunization coverage, especially among the most recently vaccinated, may contribute to attenuation of the COVID-19 spread and severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementInterdisciplinary Data Science Research (CIRD), the Hebrew University of JerusalemAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAn online tool for displaying the analytical results is available at: https://covi.shinyapps.io/COVID19/. Code and data is available at: https://github.com/nadavrap/COVID19.https://github.com/nadavrap/COVID19 https://covi.shinyapps.io/COVID19/. ER -